WO2018178497A3 - Uso de melatonina para el tratamiento de tumores - Google Patents

Uso de melatonina para el tratamiento de tumores Download PDF

Info

Publication number
WO2018178497A3
WO2018178497A3 PCT/ES2018/070289 ES2018070289W WO2018178497A3 WO 2018178497 A3 WO2018178497 A3 WO 2018178497A3 ES 2018070289 W ES2018070289 W ES 2018070289W WO 2018178497 A3 WO2018178497 A3 WO 2018178497A3
Authority
WO
WIPO (PCT)
Prior art keywords
melatonin
tumours
treatment
production
metabolites
Prior art date
Application number
PCT/ES2018/070289
Other languages
English (en)
French (fr)
Other versions
WO2018178497A2 (es
Inventor
Germaine Escames Rosa
Darío ACUÑA CASTROVIEJO
Ana GUERRA-LIBRERO RITE
Beatriz Irene FERNÁNDEZ GIL
Javier FLORIDO RUIZ
Original Assignee
Universidad De Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad De Granada filed Critical Universidad De Granada
Priority to BR112019020519A priority Critical patent/BR112019020519A2/pt
Priority to US16/498,825 priority patent/US11234964B2/en
Priority to EP18776647.2A priority patent/EP3603635A4/en
Publication of WO2018178497A2 publication Critical patent/WO2018178497A2/es
Publication of WO2018178497A3 publication Critical patent/WO2018178497A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención describe el uso de melatonina para la preparación de una composición farmacéutica apta para su administración intratumoral para el tratamiento de tumores. Esta composición comprende unas concentraciones elevadas de melatonina, derivados de melatonina o metabolitos, de forma que la melatonina ejerce un efecto oxidante, aumentando la producción de radicales libres y produciendo una activación de la muerte celular.
PCT/ES2018/070289 2017-03-31 2018-04-02 Uso de melatonina para el tratamiento de tumores WO2018178497A2 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR112019020519A BR112019020519A2 (pt) 2017-03-31 2018-04-02 uso de melatonina para o tratamento de tumores
US16/498,825 US11234964B2 (en) 2017-03-31 2018-04-02 Use of melatonin for the treatment of tumors
EP18776647.2A EP3603635A4 (en) 2017-03-31 2018-04-02 USE OF MELATONIN FOR TREATMENT OF TUMORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201730598A ES2684408B1 (es) 2017-03-31 2017-03-31 Uso de melatonina para el tratamiento de tumores
ESP201730598 2017-03-31

Publications (2)

Publication Number Publication Date
WO2018178497A2 WO2018178497A2 (es) 2018-10-04
WO2018178497A3 true WO2018178497A3 (es) 2018-11-15

Family

ID=63668610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2018/070289 WO2018178497A2 (es) 2017-03-31 2018-04-02 Uso de melatonina para el tratamiento de tumores

Country Status (5)

Country Link
US (1) US11234964B2 (es)
EP (1) EP3603635A4 (es)
BR (1) BR112019020519A2 (es)
ES (1) ES2684408B1 (es)
WO (1) WO2018178497A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984322B (zh) * 2022-06-10 2022-12-20 四川大学 一种双层水凝胶材料、其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329785A1 (en) * 2011-06-10 2014-11-06 Ramscor, Inc. Conveniently Injectable or Implantable Sustained-Release Antioxidant Formulations for Therapies of Ocular Maladies or Cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656939A1 (en) * 2004-11-10 2006-05-17 Pooger Properties Limited Use of melatonin in the manufacture of a medicament for treating cancer
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
ES2384798B1 (es) * 2011-10-19 2013-06-04 Universidad De Granada Uso de melatonina para el tratamiento y/o prevención de la mucositis.
ES2394245B2 (es) * 2012-11-28 2013-12-16 Universidad De Granada Composición de melatonina o sus derivados con coenzima q10 y su uso contra el envejecimiento de la piel
BR112016022394A2 (pt) 2014-03-27 2017-08-15 Servicio Andaluz De Salud Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329785A1 (en) * 2011-06-10 2014-11-06 Ramscor, Inc. Conveniently Injectable or Implantable Sustained-Release Antioxidant Formulations for Therapies of Ocular Maladies or Cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONG YUNKYUNG ET AL.: "Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells", JOURNAL OF PINEAL RESEARCH APR 2014, vol. 56, no. 3, 31 March 2014 (2014-03-31), pages 264 - 274, XP055548608, ISSN: 0742-3098, Retrieved from the Internet <URL:https://doi.org/10.1111/jpi.12119> *
PARK SHI-YOUNG ET AL.: "Melatonin suppresses tumor angiogenesis by inhibiting HIF-1 alpha stabilization under hypoxia", JOURNAL OF PINEAL RESEARCH ENGLAND MAR 2010, vol. 48, no. 2, 28 February 2010 (2010-02-28), pages 178 - 184, XP055548612, ISSN: 1600-079X, Retrieved from the Internet <URL:https://doi.org/10.1111/j.1600-079X.2009.00742.x> *
TRUBIANI ORIANA ET AL.: "Melatonin provokes cell death in human B-lymphoma cells by mitochondrial-dependent apoptotic pathway activation", JOURNAL OF PINEAL RESEARCH NOV 2005, vol. 39, no. 4, 31 October 2005 (2005-10-31), pages 425 - 431, XP055548617, ISSN: 0742-3098, Retrieved from the Internet <URL:https://doi.org/10.1111/j.1600-079X.2005.00270.x> *

Also Published As

Publication number Publication date
ES2684408A1 (es) 2018-10-02
US11234964B2 (en) 2022-02-01
EP3603635A2 (en) 2020-02-05
US20210106562A1 (en) 2021-04-15
EP3603635A4 (en) 2021-01-20
WO2018178497A2 (es) 2018-10-04
BR112019020519A2 (pt) 2020-05-05
ES2684408B1 (es) 2019-07-09

Similar Documents

Publication Publication Date Title
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CA2956871C (en) Compounds active towards bromodomains
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MY196173A (en) Cot Modulators And Methods Of Use Thereof
WO2018067512A8 (en) SPIROCYCLIC COMPOUNDS
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
MX2023009205A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
EP4223297A3 (en) Administration and dosage of diaminophenothiazines
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
MX2022008478A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
TW201613594A (en) Pharmaceutical composition containing diamino heteroring carboxamide derivatives
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
WO2018178497A3 (es) Uso de melatonina para el tratamiento de tumores
MX2020000491A (es) Moduladores terapeuticos del modo inverso de la atp sintasa.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019020519

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018776647

Country of ref document: EP

Effective date: 20191031

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18776647

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112019020519

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190930